Risks associated with the therapeutic use of fluoroquinolones

Bibliography

• Lode H, Rubinstein E. Adverse effects. In: Hooper D, Rubinstein E, editors. Quinolone antimicrobial agents. 3rd edition. American Society for Microbiology, Washington; 2003. p. 407-19
   Google Scholar
• Owens RC Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41(Suppl 2):S144-57
   PubMed Web of Science ®Google Scholar
• van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009;32:359-578
   PubMed Web of Science ®Google Scholar
• Liu HH. Safety profile of the fluoroquinolones: focus on levofloxacin. Drug Saf 2010;33:353-69
   PubMed Web of Science ®Google Scholar
• Stahlmann R, Lode H. Safety overview. Toxicity, adverse effects, and drug interactions. In: Andriole V, editor. The Quinolones. 3rd edition. Academic Press, London; 2000. p. 397-453
   Google Scholar
• Stahlmann R. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett 2002;127:269-77
   PubMed Web of Science ®Google Scholar
• Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr Opin Pharmacol 2012;12:527-34
   PubMed Web of Science ®Google Scholar
• Spigaglia P, Barbanti F, Mastrantonio P, et al. European study group on Clostridium difficile (ESGCD). fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 2008;57:784-9
   PubMed Web of Science ®Google Scholar
• Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 2012;55(Suppl 2):S65-70
   PubMed Web of Science ®Google Scholar
• Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60
   PubMed Web of Science ®Google Scholar
• Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-703
   PubMed Web of Science ®Google Scholar
• Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother 2011;66:1431-46
   PubMed Web of Science ®Google Scholar
• Paterson JM, Mamdani MM, Manno M, Juurlink DN. Canadian drug safety and effectiveness research network. fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ 2012;184:1565-70
   PubMed Web of Science ®Google Scholar
• Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006(7):639-51
   PubMedGoogle Scholar
• Samarakoon N, Harrisberg B, Ell J. Ciprofloxacin-induced toxic optic neuropathy. Clin Experiment Ophthalmol 2007;35:102-4
   PubMed Web of Science ®Google Scholar
• Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA 2012;307:1414-19
   PubMed Web of Science ®Google Scholar
• Albini TA, Karakousis PC, Abbey AM, et al. Association between oral fluoroquinolones and retinal detachment. Am J Ophthalmol 2012;154:919-21
   PubMed Web of Science ®Google Scholar
• Han DP, Szabo A. Flashes, floaters, and oral fluoroquinolones. Arch Ophthalmol 2013;131:91-3
   Google Scholar
• Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006;43:1603-11
   PubMed Web of Science ®Google Scholar
• Briasoulis A, Agarwal V, Pierce WJ. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011;120:103-10
   PubMed Web of Science ®Google Scholar
• Zambon A, Polo Friz H, Contiero P, Corrao G. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf 2009;32:159-67
   PubMed Web of Science ®Google Scholar
• Ray WA, Murray KT, Hallet al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90
   PubMed Web of Science ®Google Scholar
• Zeuli JD, Wilson JW, Estes LL. The Effect of combination fluoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob Agents Chemother 2013;57:1121-7
   PubMed Web of Science ®Google Scholar
• Lapi F, Wilchesky M, Kezouh A, et al. Fluoroquinolones and the risk of serious arrhythmia: a population-based study. Clin Infect Dis 2012;55:1457-65
   PubMed Web of Science ®Google Scholar
• Morganroth J, Dimarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005;128:3398-406
   PubMed Web of Science ®Google Scholar
• Koide T, Shiba M, Tanaka K, et al. Severe QT interval prolongation associated with moxifloxacin: a case report. Cases J 2008;1:409
   PubMedGoogle Scholar
• Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004;75:242-7
   PubMed Web of Science ®Google Scholar
• Graumlich JF, Habis S, Avelino RR, et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 2005;25:1296-302
   PubMed Web of Science ®Google Scholar
• Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-61
   PubMed Web of Science ®Google Scholar
• Aspinall SL, Good CB, Jiang R et al. Severe dysglycemia with the fluoroquinolones: a class effect? Clin Infect Dis 2009;49:402-8
   PubMed Web of Science ®Google Scholar
• Schelleman H, Bilker WB, Brensinger CM, et al. Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin Pharmacol Ther 2010;88:214-22
   PubMed Web of Science ®Google Scholar
• Cohlan SQ, Bevelander G, Tiamsic T. Growth inhibition of prematures receiving tetracycline. Am J Dis Child 1963;105:453-61
   Google Scholar
• Channa HM, Ashfaq M, Mastoi SMQureshi MA, et al. Effect of ciprofloxacin on growing cartilage in albino rat pups. J Ayub Med Coll Abbottabad 2006;18:50-4
   PubMedGoogle Scholar
• Stahlmann R. Effects on connective tissue structures. In: Hooper D, Rubinstein E, editors. Quinolone antimicrobial agents. 3rd edition. American Society for Microbiology, Washington; 2003. p. 441-9
   Google Scholar
• Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009;33:194-200
   PubMed Web of Science ®Google Scholar
• Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child 2011;96:874-80
   PubMed Web of Science ®Google Scholar
• Bayer. Full prescribing information, Cipro®, October 2011
   Google Scholar
• Arguedas A, Dagan R, Pichichero M, et al. An open-label, double tympanocentesis study of levofloxacin therapy in children with, or at high risk for, recurrent or persistent acute otitis media. Pediatr Infect Dis J 2006;25:1102-9
   PubMed Web of Science ®Google Scholar
• Bradley JS, Arguedas A, Blumer JL, et al. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J 2007;26:868-78
   PubMed Web of Science ®Google Scholar
• Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007;26:879-91
   PubMed Web of Science ®Google Scholar
• Noel GJ, Blumer JL, Pichichero ME, et al. A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr Infect Dis J 2008;27:483-9
   PubMed Web of Science ®Google Scholar
• Schaad UB. Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J 2007;26:865-7
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Arguedas A, Dagan R, et al. Safety and efficacy of gatifloxacin therapy for children with recurrent acute otitis media (AOM) and/or AOM treatment failure. Clin Infect Dis 2005;41:470-8
   PubMed Web of Science ®Google Scholar
• Pinon M, Scolfaro C, Bignamini E, et al. Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin. Pediatrics 2010;126:e1253-6
   PubMed Web of Science ®Google Scholar
• Torres JR, Bajares A. Severe acute polyarthritis in a child after high doses of moxifloxacin. Scand J Infect Dis 2008;40:582-4
   PubMed Web of Science ®Google Scholar
• Gottschalk AW, Bachman JW. Death following bilateral complete Achilles tendon rupture in a patient on fluoroquinolone therapy: a case report. J Med Case Rep 2009;3:1
   PubMedGoogle Scholar
• van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001;45:235-9
   PubMed Web of Science ®Google Scholar
• van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 2002;324:1306-7
   PubMed Web of Science ®Google Scholar
• Khaliq Y, Zhanel GG. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 2003;36:1404-10
   PubMed Web of Science ®Google Scholar
• Wise BL, Peloquin C, Choi H, et al. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012;125:1228.e23-1228. e28
   PubMed Web of Science ®Google Scholar
• Sendzik J, Shakibaei M, Schäfer-Korting M, Stahlmann R. Fluoroquinolones cause changes in extracellular matrix, signalling proteins, metalloproteinases and caspase-3 in cultured human tendon cells. Toxicology 2005;212:24-36
   PubMed Web of Science ®Google Scholar
• Sendzik J, Shakibaei M, Schäfer-Korting M, et al. Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. Int J Antimicrob Agents 2010;35:366-74
   PubMed Web of Science ®Google Scholar
• Lode H. Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. Am J Med 2010;123:S26-38
   PubMed Web of Science ®Google Scholar
• Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010;27:193-209
   PubMed Web of Science ®Google Scholar
• Shaughnessy MK, Amundson WH, Kuskowski MA, et al. Unnecessary antimicrobial use in patients with current or recent Clostridium difficile infection. Infect Control Hosp Epidemiol 2013;34:109-16
   PubMed Web of Science ®Google Scholar
• Keijsers CJ, van Hensbergen L, Jacobs L, et al. Geriatric pharmacology and pharmacotherapy education for health professionals and students: a systematic review. Br J Clin Pharmacol 2012;74:762-73
   PubMed Web of Science ®Google Scholar